LAVAL, QUEBEC, CANADA, – February 6, 2014 – ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX:
PFSCF), ("ProMetic" or the "Corporation") announced today the appointment of Dr. John Moran as its new Chief Medical Officer ("CMO"), effective as of March 1st, 2014.
Before joining ProMetic as its new CMO, Dr. Moran MD, FRACP, FACP, FACPE, served as Vice President, Clinical Affairs – Home Modalities at DaVita HealthCare Partners, Inc. where he was responsible for the quality of care and related business issues for over 20,000 home dialysis patients in over 900 care
centers. Dr. Moran is also a Consulting Professor in the Division of Nephrology at Stanford University School of Medicine. Previously, Dr. Moran served for 7 years as Senior Vice President, Clinical Affairs for Satellite Healthcare, 4 years as Senior Vice President and Chief Medical Officer for Vasca Inc. and more than 3 years as Vice President for Clinical Development and Marketing for the Renal Division of Baxter Healthcare Corporation.
"I am thrilled to be joining ProMetic as its new Chief Medical Officer at such a critical time in its clinical development phase. As a member of ProMetic's Board of Directors for the past 2 years, I have closely followed the expansion of ProMetic's compounds into a compelling therapeutic franchise. As a physician, it will be my privilege to see ProMetic's small molecule drug candidates and plasma derived therapeutics finally address many severe unmet medical conditions and so significantly improve the quality of life and
outcomes for potentially thousands of patients" said Dr. Moran. "As evidenced by the first-in-class efficacy demonstrated in some of the most stringent preclinical fibrotic models and the recent successful operational launch of the plasma purification facility, ProMetic is now well positioned to become a leading provider of innovative medical therapies", added Dr. Moran.
"Our recent progress and further anticipated advancement of our lead drug candidates have made the creation of the Chief Medical Officer position a corporate priority. We believe that Dr. Moran is the perfect candidate to help us successfully bring forward our compounds through the regulatory pathway given
his deep knowledge of both ProMetic and industry at large. His wealth of expertise in senior executive positions related to clinical affairs, clinical development and marketing in the field of nephrology and end-stage renal diseases will play a key role in the development of our valuable clinical assets", commented Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (prometic.com) is a long established biopharmaceutical company with
globally recognized expertise in bioseparation, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic
proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, cancer and autoimmune diseases/inflammation. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe and Asia.
Forward Looking Statements
This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds
and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 26 of ProMetic's Annual Information Form for the year ended December 31, 2012, under the heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars
unless indicated otherwise.